CNSP

Insider Trades

Name	Value	Action	Price	Current Price
Charles Faith L.Director $34k7.1k shares BuyMay 18, 2026 $4.79 --

News

accessnewswire.comCNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segmentaccessnewswire.comJun 8

accessnewswire.comCNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progressaccessnewswire.comMay 20

247wallst.comForget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6247wallst.comMay 14

accessnewswire.comCNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progressaccessnewswire.comMay 14

benzinga.comWhat's Going On With CNS Pharmaceuticals Stock On Wednesday?benzinga.comMay 6

Trade CNSP

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.

CEO: Rami Levin
IPO Date: Nov 8, 2019

Market Data

Volume: 41.9K

Valuation

Market Cap: $2.8M

Financials

Financial statement snapshot is not available yet.

Events

EarningsAug 17

EPS est. -0.24